Flex Pharma, Inc., a Boston MA-based biopharmaceutical company that develops treatments for neuromuscular disorders, raised $40m in funding.
Backers included:
Longwood Fund
Bessemer Venture Partners
EcoR1 Capital
Jennison Associates LLC (on behalf of clients)
Lightstone Ventures
Alexandria Equities LLC
CD-Venture GmbH
Bindley Capital Partners LLC
City Hill Ventures
Richard Mark Beleson, retired SVP, Capital Research Company
Todd Dagres, Spark Capital General Partner
Richard Gibbs, Gibbs Capital Management
Daniel Gold, Managing Partner, Founder, CEO, QVT Financial LP
Wyc Grousbeck, Boston Celtics Managing Partner and CEO
Robert Steven Kaplan, Ph.D., Harvard Business School Professor
The Kraft Group
Peter S. Lynch, Trustee – The Lynch Foundation
John Maraganore, Ph.D., Alnylam CEO
Judy Pagliuca, Managing Partner, Pags Growth Capital
Steve Pagliuca, Bain Capital Managing Director, Boston Celtics Managing Partner
William Sahlman, Ph.D., Harvard Business School Professor
Diane and John Sculley, former Apple CEO & Sculley Family Office
Jonathan Seelig, Co-founder Akamai Technologies
The company intends to use the funds to advance the science and its clinical candidates addressing neuromuscular disorders.
Founded by Rod MacKinnon, M.D. (2003 Nobel Laureate) and Bruce Bean, Ph.D., Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D., Flex Pharma has demonstrated initial human efficacy related to muscle cramping in healthy volunteers. The company plans to initiate efficacy studies in patients with neuromuscular disorders in the first half of 2015.
FinSMEs
09/09/2014